2/9/2021 8:04:15 AM
Curis Doses First Patient In Phase 1 Study Of CA-4948 With Ibrutinib In Patients With R/R Hematologic Malignancies
2/2/2021 8:05:51 AM
Curis Begins Phase 2 LUCAS Study Of CA-4948 For Anemia In Patients With Myelodysplastic Syndromes
12/14/2020 8:09:05 AM
Curis Says Closes Underwritten Public Offering Of 29.5 Mln Shares With $169.6 Mln In Gross Proceeds
12/9/2020 9:31:50 AM
Curis Prices Public Offering Of 25.65 Mln Shares At $5.75 Per Share
12/8/2020 7:07:56 AM
Curis Reports Positive Preliminary Data From Phase 1 Study Of CA-4948 Monotherapy In Patients With AML Or High-risk MDS
12/2/2020 8:43:10 AM
Curis To Discuss CA-4948 Clinical Data On Non-Hodgkin Lymphoma, Acute Myeloid Leukemia
11/10/2020 4:07:32 PM
Curis Q3 Loss/Shr $0.11 Vs Loss $0.19 Prior Year
10/21/2020 8:07:22 AM
Curis Highlights Publication In ACS Medicinal Chemistry Letters Showcasing Ideal Pharmacologic Properties Of CA-4948
8/4/2020 4:03:07 PM
Curis Q2 Net Loss $6.7 Mln Or $0.17/Shr Vs Net Loss $7.2 Mln Or $0.22/Shr Last Year